863 related articles for article (PubMed ID: 33925129)
1. Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue.
Gote V; Nookala AR; Bolla PK; Pal D
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925129
[TBL] [Abstract][Full Text] [Related]
2. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
3. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
4. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
5. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
[TBL] [Abstract][Full Text] [Related]
6. Combination Organelle Mitochondrial Endoplasmic Reticulum Therapy (COMET) for Multidrug Resistant Breast Cancer.
Milane LS; Dolare S; Ren G; Amiji M
J Control Release; 2023 Nov; 363():435-451. PubMed ID: 37717658
[TBL] [Abstract][Full Text] [Related]
7. Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology.
Xue X; Liang XJ
Chin J Cancer; 2012 Feb; 31(2):100-9. PubMed ID: 22237039
[TBL] [Abstract][Full Text] [Related]
8. MSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition.
He Q; Shi J
Adv Mater; 2014 Jan; 26(3):391-411. PubMed ID: 24142549
[TBL] [Abstract][Full Text] [Related]
9. Diethyldithiocarbamate-copper nanocomplex reinforces disulfiram chemotherapeutic efficacy through light-triggered nuclear targeting.
Ren L; Feng W; Shao J; Ma J; Xu M; Zhu BZ; Zheng N; Liu S
Theranostics; 2020; 10(14):6384-6398. PubMed ID: 32483459
[TBL] [Abstract][Full Text] [Related]
10. Novel nanomedicines to overcome cancer multidrug resistance.
Su Z; Dong S; Zhao SC; Liu K; Tan Y; Jiang X; Assaraf YG; Qin B; Chen ZS; Zou C
Drug Resist Updat; 2021 Sep; 58():100777. PubMed ID: 34481195
[TBL] [Abstract][Full Text] [Related]
11. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
[TBL] [Abstract][Full Text] [Related]
12. Multifunctional nanoplatforms co-delivering combinatorial dual-drug for eliminating cancer multidrug resistance.
Wei X; Song M; Li W; Huang J; Yang G; Wang Y
Theranostics; 2021; 11(13):6334-6354. PubMed ID: 33995661
[TBL] [Abstract][Full Text] [Related]
13. IMD-0354 targets breast cancer stem cells: a novel approach for an adjuvant to chemotherapy to prevent multidrug resistance in a murine model.
Gomez-Cabrero A; Wrasidlo W; Reisfeld RA
PLoS One; 2013; 8(8):e73607. PubMed ID: 24014113
[TBL] [Abstract][Full Text] [Related]
14. Stimuli-Responsive Nanomedicines for Overcoming Cancer Multidrug Resistance.
Zhou L; Wang H; Li Y
Theranostics; 2018; 8(4):1059-1074. PubMed ID: 29463999
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer.
Yuan Y; Cai T; Xia X; Zhang R; Chiba P; Cai Y
Drug Deliv; 2016 Nov; 23(9):3350-3357. PubMed ID: 27098896
[TBL] [Abstract][Full Text] [Related]
16. Nanomedicine to overcome cancer multidrug resistance.
Yang X; Yi C; Luo N; Gong C
Curr Drug Metab; 2014; 15(6):632-49. PubMed ID: 25255871
[TBL] [Abstract][Full Text] [Related]
17. Indocyanine green/doxorubicin-encapsulated functionalized nanoparticles for effective combination therapy against human MDR breast cancer.
Chen HH; Lu IL; Liu TI; Tsai YC; Chiang WH; Lin SC; Chiu HC
Colloids Surf B Biointerfaces; 2019 May; 177():294-305. PubMed ID: 30771581
[TBL] [Abstract][Full Text] [Related]
18. Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy.
Beretta GL; Cavalieri F
Curr Med Chem; 2016; 23(1):3-22. PubMed ID: 26438248
[TBL] [Abstract][Full Text] [Related]
19. Novel dendritic polyglycerol-conjugated, mesoporous silica-based targeting nanocarriers for co-delivery of doxorubicin and tariquidar to overcome multidrug resistance in breast cancer stem cells.
Pan Y; Zhou S; Li Y; Parshad B; Li W; Haag R
J Control Release; 2021 Feb; 330():1106-1117. PubMed ID: 33189788
[TBL] [Abstract][Full Text] [Related]
20. Combating P-glycoprotein-mediated multidrug resistance using therapeutic nanoparticles.
Zhang Q; Li F
Curr Pharm Des; 2013; 19(37):6655-66. PubMed ID: 23621532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
